Stock of Dishman zooms 20 per cent on USFDA license for cancer drug

Dishman Pharmaceuticals and Chemicals is one of the API supplier of Zejula Capsules, and it has recently got the approval from United States Food and Drug Administration (USFDA) for its cancer drug for Tesaro Inc.

Due to the effect of which, the stock of Dishman has been locked at upper circuit in Tuesday’s opening trading session on the bourses. It zoomed by 20 per cent, and was trading at Rs 278.70, up by Rs 46.45 or 19.99 per cent.

The stock hit its 52-week high of Rs 278.20, leaving the total bid orders of 154,858 shares in pending mode, with a zero sellers situation.

It has offered more than 43 per cent returns over a one year duration, outperforming the BSE Small-cap and BSE Healthcare indices over the same period of time.

Dishman Pharmaceuticals and Chemicals is a multinational company, which is engaged in producing active ingredients in the pharmaceutical sector. It is an outsourcing associate for the pharmaceutical industry.

The Company manufactures and supplies active ingredients, chemicals and different kinds of pharmaceutical products to pharmaceutical industries and cosmetics and other similar industries.